Pulmonx Valuation Multiples

Pulmonx Overview

About Pulmonx

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Founded

1995

HQ

Employees

291

Website

pulmonx.com

Sectors

Medical DevicesDeepTechHealthTech

Financials (LTM)

Revenue: $91M

EBITDA: ($33M)

EV

$44M

Valuation Multiples

Multiples.vc

Start free trial

Pulmonx Financials

Pulmonx reported last 12-month revenue of $91M and negative EBITDA of ($33M).

In the same LTM period, Pulmonx generated $67M in gross profit, ($33M) in EBITDA losses, and had net loss of ($52M).

Pulmonx P&L

In the most recent fiscal year, Pulmonx reported revenue of $90M and EBITDA of ($35M).

Pulmonx expects next 12-month revenue of XXX and NTM EBITDA of XXX

Pulmonx Stock Performance

Pulmonx has current market cap of $58M, and enterprise value of $44M.

Pulmonx's stock price is $1.37.

Pulmonx Valuation Multiples

Pulmonx trades at 0.5x EV/Revenue multiple, and (1.3x) EV/EBITDA.

Pulmonx Financial Valuation Multiples

As of April 11, 2026, Pulmonx has market cap of $58M and EV of $44M.

Equity research analysts estimate Pulmonx's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Pulmonx has a P/E ratio of (1.1x).

Pulmonx Margins & Growth Rates

Pulmonx's revenue in the last 12 month grew by 5%.

Pulmonx's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.4M for the same period.

Pulmonx's rule of 40 is (30%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Pulmonx's rule of X is (29%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Pulmonx Public Comps

See public comps and valuation multiples for other Medical Devices comps.

Pulmonx M&A Activity

Pulmonx acquired XXX companies to date.

Last acquisition by Pulmonx was on XXXXXXXX, XXXXX. Pulmonx acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Pulmonx Investment Activity

Pulmonx invested in XXX companies to date.

Pulmonx made its latest investment on XXXXXXXX, XXXXX. Pulmonx invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).